BidaskClub lowered shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) from a sell rating to a strong sell rating in a research note published on Saturday morning.

A number of other equities analysts also recently weighed in on CRBP. Noble Financial reaffirmed a buy rating on shares of Corbus Pharmaceuticals Holdings in a research report on Friday, April 7th. Cantor Fitzgerald set a $24.00 price target on Corbus Pharmaceuticals Holdings and gave the stock a buy rating in a research report on Tuesday, May 9th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Corbus Pharmaceuticals Holdings currently has an average rating of Buy and a consensus price target of $20.50.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) traded up 5.26% during trading on Friday, hitting $6.00. 320,710 shares of the stock were exchanged. The firm’s 50 day moving average price is $6.26 and its 200-day moving average price is $7.15. Corbus Pharmaceuticals Holdings has a 1-year low of $2.80 and a 1-year high of $10.78. The stock’s market cap is $301.31 million.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.16). Corbus Pharmaceuticals Holdings had a negative return on equity of 117.78% and a negative net margin of 874.41%. The firm had revenue of $1.29 million during the quarter, compared to the consensus estimate of $2.50 million. On average, analysts anticipate that Corbus Pharmaceuticals Holdings will post ($0.77) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/06/bidaskclub-downgrades-corbus-pharmaceuticals-holdings-inc-nasdaqcrbp-to-strong-sell.html.

Large investors have recently made changes to their positions in the company. FMR LLC bought a new stake in shares of Corbus Pharmaceuticals Holdings during the fourth quarter worth about $9,331,000. Highbridge Capital Management LLC boosted its stake in shares of Corbus Pharmaceuticals Holdings by 38.4% in the first quarter. Highbridge Capital Management LLC now owns 73,696 shares of the biopharmaceutical company’s stock worth $608,000 after buying an additional 20,437 shares in the last quarter. Evanson Asset Management LLC boosted its stake in shares of Corbus Pharmaceuticals Holdings by 1.8% in the first quarter. Evanson Asset Management LLC now owns 20,360 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 360 shares in the last quarter. BlueCrest Capital Management Ltd bought a new stake in shares of Corbus Pharmaceuticals Holdings during the first quarter worth about $246,000. Finally, Segantii Capital Management Ltd boosted its stake in shares of Corbus Pharmaceuticals Holdings by 683.3% in the first quarter. Segantii Capital Management Ltd now owns 56,400 shares of the biopharmaceutical company’s stock worth $465,000 after buying an additional 49,200 shares in the last quarter. Institutional investors own 28.12% of the company’s stock.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.